English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives: Review of the EU regulations concerning substitution of biological products with biosimilar products . Methods: The TPPC task force has checked the approach to automatic substitution by WHO, at the EMA level and in countries across European Union. An internet search was performed checking the regulations and direct contact to Regulatory Agencies in all European Union member states. Results: Based on the research we have obtained directly information from 23 EU Member States and Switzerland. Most of the EU countries do not allow for automatic substitution of the reference biological medicinal product by a biosimilar. Currently some EU countries already have local legal regulations towards automatic substitution of medicinal products in place. Conclusions: Due to medicinal product complexity in most of the European Union countries the automatic substitution of a reference biological product by a biosimilar product is not allowed. Local regulations are needed in each of the Member States according to EMA guidance.

journal of health policy and outcomes research

Biosimilar drugs – automatic substitution regulations review. Polish ISPOR chapter’s Therapeutic Programs and Pharmaceutical Care (TPPC) task force report